128868-60-0

Basic information

• Product Name: 4-BROMOBENZOFURAN
• Synonyms: 4-BROMOBENZOFURAN;4-BroMobenzo[b]furan;4-BroMo-1-benzofuran;Benzofuran, 4-broMo-
• CAS NO: 128868-60-0
• Molecular Formula: C₈H₅BrO
• Molecular Weight: 197.04
• Product Categories: Aromatics;Heterocycles;Intermediates
• Mol File: 128868-60-0.mol

Chemical Properties

• Boiling Point: 233.807°C at 760 mmHg
• Flash Point: 95.203°C
• Appearance: /
• Density: 1.608g/cm³
• Vapor Pressure: 0.084mmHg at 25°C
• Refractive Index: 1.639
• Storage Temp.: 2-8°C
• Solubility: Acetone, Chloroform, Ethyl Acetate
• CAS DataBase Reference: 4-BROMOBENZOFURAN(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOBENZOFURAN(128868-60-0)
• EPA Substance Registry System: 4-BROMOBENZOFURAN(128868-60-0)

Safety Data

• Hazardous Substances Data: 128868-60-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMOBENZOFURAN is used as a chemical intermediate for the preparation of aminoalkylbenzofurans, which act as 5-HT2C agonists. These compounds have potential applications in the development of antiobesity and antidepressant medications, making them valuable in the pharmaceutical industry for addressing significant health concerns.

InChI:InChI=1/C8H5BrO/c9-7-2-1-3-8-6(7)4-5-10-8/h1-5H

Upstream product

• 166281-37-4 2-bromo-4,5-difluorophenol 
• 76574-33-9 2-(2,6-dibromophenyl)acetaldehyde 
• 608-30-0 2,6-dibromoaniline 
• 591-20-8 3-Bromophenol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 204452-94-8 2-(3-bromophenoxy)acetaldehyde diethyl acetal 
• 443-81-2 2-bromo-3-fluorophenol 
• 150-19-6 O-methylresorcine 
• 135999-16-5 2-Bromo-3-methoxyphennol 
• 695-96-5 2-bromo-4-chlorophenol 
• 17332-11-5 2-bromo-4-methoxyphenol 
• 286836-06-4 2-(2-bromo-3-fluorophenoxy)-acetaldehyde diethyl acetal 
• 106-41-2 4-bromo-phenol 
• 95-56-7 2-hydroxybromobenzene 

Downstream Products

• 95333-17-8 benzofuran-4-carbonitrile 
• 325487-30-7 1-benzyl-3-methyl-4-hydroxy-4-(benzofuran-4-yl)piperidine 

Relevant articles and documents

Bipolar fluorescent material based on benzoquinary heterocyclic ring and preparation method thereof and organic electroluminescent device

The present invention discloses a bipolar fluorescent material based on a benzoquinary heterocyclic ring and a preparation method thereof with an organic electroluminescent device, the bipolar fluorescent material having the following structure shown: or

Five-membered heterocyclic oxo carboxylic acid compound and medical application thereof

The invention relates to a five-membered heterocyclic oxo carboxylic acid compound and a medical application thereof. Specifically, the invention relates to a compound, a pharmaceutical salt, a prodrug, a hydrate, a solvate or a crystal form as shown in a formula (I), and also relates to a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the pharmaceutical composition as a secretion regulator of interferon type I, especially as an STING agonist in preparation of medicines for preventing and/or treating I-type interferon related diseases.

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER

Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

Pyrimidine or pyrazino five-membered heterocyclic compound and applications thereof

The invention discloses a pyrimidine or pyrazino five-membered heterocyclic compound, a pharmaceutically acceptable salt, a hydrate, a prodrug, a stereoisomer or a solvate thereof, and provides a preparation method of the compound, a composition containing the compound, and applications of the compound in preparation of drugs for treating diseases or disorders related to the action mechanism of EED protein and/or PRC2 protein complex.

Dioxazolones as masked ester surrogates in the Pd(ii)-catalyzed direct C-H arylation of 6,5-fused heterocycles

A simple and effective Pd(ii)-catalyzed regioselective C(2)-H arylation of 6,5-fused heterocycles with dioxazolones as a masked ester surrogate under mild conditions is reported. The significance of the arylation is highlighted by the new reactivity demonstrated in dioxazolones via proximal C-H activation of the cyclic carbonate of the hydroxamic acid functionality under protic conditions.

PRC2 INHIBITORS

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))

Pyrimidone compound and application thereof

The invention discloses a pyrimidone compound, pharmaceutically acceptable salt and solvate thereof, and provides a method for preparing the compounds, a composition containing the compounds and medicinal application of the compounds in preparation of medicines for treating diseases or disorders related to EED protein and/or PRC2 protein complex action mechanisms.

Pyrido/pyridazocyclic compound and application thereof

The invention discloses a pyrido/pyridazocyclic compound, a pharmaceutically acceptable salt and a solvent compound thereof. The invention further provides a preparation method of the compound, a composition with the compound and application of the compound for preparing medicines for treating diseases or disorders related to EED (embryonic ectoderm development) protein and/or PRC2 (polycomb repressive complex 2) protein composition action mechanisms.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.